These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
82 related items for PubMed ID: 15609128
1. Bone mineral density and adjuvant therapy in breast cancer survivors. Crandall C, Petersen L, Ganz PA, Greendale GA. Breast Cancer Res Treat; 2004 Dec; 88(3):257-61. PubMed ID: 15609128 [Abstract] [Full Text] [Related]
2. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. J Clin Oncol; 2006 Feb 01; 24(4):675-80. PubMed ID: 16446340 [Abstract] [Full Text] [Related]
3. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE. J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845 [Abstract] [Full Text] [Related]
8. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Bone; 2007 Sep 01; 41(3):346-52. PubMed ID: 17618847 [Abstract] [Full Text] [Related]
10. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy. Schwartz AL, Winters-Stone K, Gallucci B. Oncol Nurs Forum; 2007 May 01; 34(3):627-33. PubMed ID: 17573321 [Abstract] [Full Text] [Related]
11. The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy. Vehmanen LK, Elomaa I, Blomqvist CP, Saarto T. Acta Oncol; 2014 Jan 01; 53(1):75-9. PubMed ID: 23713891 [Abstract] [Full Text] [Related]
12. Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Shapiro CL, Phillips G, Van Poznak CH, Jackson R, Leboff MS, Woodard S, Lemeshow S. Breast Cancer Res Treat; 2005 Mar 01; 90(1):41-6. PubMed ID: 15770525 [Abstract] [Full Text] [Related]
13. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R. Clin Cancer Res; 2005 Aug 15; 11(16):5671-7. PubMed ID: 16115902 [Abstract] [Full Text] [Related]
17. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. Swenson KK, Nissen MJ, Anderson E, Shapiro A, Schousboe J, Leach J. J Support Oncol; 2009 Aug 15; 7(3):101-7. PubMed ID: 19507458 [Abstract] [Full Text] [Related]
19. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA. J Clin Oncol; 2007 Mar 01; 25(7):829-36. PubMed ID: 17159193 [Abstract] [Full Text] [Related]